Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials
Open accessThe DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index; 7 of the 21 sources its claims cite were checked for support.
Abstract
Background Metabolic syndrome (MetS) is a prevalent metabolic disease that significantly increases the risk of type 2 diabetes, cardiovascular diseases, and overall mortality. Current medications have limited effects on the various components of MetS. Berberine has demonstrated unique comprehensive therapeutic benefits for MetS, but its efficacy remains uncertain. Objective To comprehensively evaluate the efficacy and safety of berberine on MetS indicators. Methods Our study provides a comprehensive evaluation of the efficacy and safety of berberine for MetS components through systematic review and meta-analysis, from the aspects of study characteristics, risk of bias, meta-analysis, sensitivity analysis, meta-regression, and publication bias. Results The results indicate that berberine significantly reduces triglycerides (TG) (WMD: −0.367 mmol/L; 95% CI: −0.560 to −0.175; p < 0.001), fasting plasma glucose (FPG) (WMD: −0.515 mmol/L; 95% CI: −0.847 to −0.183; p = 0.002), and waist circumference (WC) (WMD: −3.270 cm; 95% CI: −4.818 to −1.722; p < 0.001) among the components of MetS, but has no significant effect on high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), or diastolic blood pressure (DBP). Additionally, berberine also improves the secondary indicators of low-density lipoprotein cholesterol (LDL-C) (WMD: −0.495 mmol/L; 95% CI: −0.714 to −0.276; p < 0.001), total cholesterol (TC) (WMD: −0.451 mmol/L; 95% CI: −0.631 to −0.271; p < 0.001), body mass index (BMI) (WMD: −0.435 kg/m 2 ; 95% CI: −0.856 to −0.013; p = 0.043), and 2-h oral glucose tolerance (2hOGTT) (WMD: −1.606 mmol/L; 95% CI: −1.891 to −1.321; p < 0.001). Meta-regression and subgroup analyses indicate that short-term treatment (≤90 days) is more effective for HDL-C and LDL-C than long-term treatment. Regarding safety, no significant difference was observed between berberine and placebo. Conclusion Berberine significantly improves glucose and lipid metabolism and has notable effects on components of MetS, including TG, FPG, and WC, with a favorable safety profile. It may serve as a beneficial supplement. Meanwhile, more high-quality, rigorously designed randomized controlled trials are needed in the future to provide stronger evidence. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024588614 .
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 12 randomized placebo-controlled trials (889 participants) found berberine significantly reduced TG, FPG, WC, and secondary LDL-C, TC, BMI, and 2hOGTT, but not HDL-C, SBP, or DBP, with no significant safety difference versus placebo. Short-term treatment (≤90 days) was more effective for HDL-C and LDL-C than longer treatment.
Key findings
- Berberine significantly reduced TG (WMD: −0.367 mmol/L; 95% CI: −0.560 to −0.175; p < 0.001; I² = 81.2%), FPG (WMD: −0.515 mmol/L; 95% CI: −0.847 to −0.183; p = 0.002; I² = 89.8%), and WC (WMD: −3.270 cm; 95% CI: −4.818 to −1.722; p < 0.001; I² = 0.00%).
- No significant effect was found on HDL-C (WMD: 0.016 mmol/L; 95% CI: −0.045 to 0.078; p = 0.60), SBP (WMD: −0.879 mmHg; 95% CI: −7.223 to 5.464; p = 0.786), or DBP (WMD: 0.424 mmHg; 95% CI: −4.894 to 5.741; p = 0.876).
- Secondary outcomes improved: LDL-C (WMD: −0.495 mmol/L; 95% CI: −0.714 to −0.276; p < 0.001), TC (WMD: −0.451 mmol/L; 95% CI: −0.631 to −0.271; p < 0.001), BMI (WMD: −0.435 kg/m²; 95% CI: −0.856 to −0.013; p = 0.043), and 2hOGTT (WMD: −1.606 mmol/L; 95% CI: −1.891 to −1.321; p < 0.001).
- Safety showed no significant difference versus placebo: pooled RR for any adverse event 1.07 (95% CI: 0.15–6.76; p = 0.746), any gastrointestinal adverse event 1.44 (95% CI: 0.85–2.42; p = 0.172), and stool abnormalities 1.52 (95% CI: 0.67–3.44; p = 0.314). Short-term treatment (≤90 days) was more effective for HDL-C and LDL-C than long-term treatment.
Methods
- Systematic review and meta-analysis of randomized placebo-controlled trials comparing purified berberine versus placebo; databases searched were PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure from inception to 15 November 2024, with no language restrictions; PROSPERO registration CRD42024588614.
- Twelve parallel placebo-controlled RCTs published between 2004 and 2023 were included, totaling 889 participants; populations included dyslipidemia, T2DM-associated dyslipidemia, hyperglycemia, drug-induced impaired fasting glucose, prediabetes, PCOS with infertility, high HDL-C syndrome, metabolic syndrome, and HIV-infected individuals with metabolic syndrome; berberine dosages ranged from 300 to 1,500 mg/day and intervention durations from 84 to 140 days.
- Analyses used STATA 17.0 (safety in Python 3.12), reporting weighted mean differences with 95% CIs; random-effects models were used when I² > 50% and fixed-effects models when I² ≤ 50%; subgroup analyses, meta-regression, sensitivity analysis, and publication-bias assessment (funnel plots, Egger’s test, Begg-Mazumdar test, trim-and-fill) were performed; risk of bias was assessed with Cochrane RoB 2.
Limitations
- The paper states substantial heterogeneity remained for TG, HDL-C, LDL-C, and FPG despite subgroup and meta-regression analyses; included studies had methodological shortcomings; populations varied; subgroup analyses for WC, SBP, DBP, and 2hOGTT could not be performed due to limited study numbers; safety data were incomplete in several studies and two of 12 included studies lacked safety data; current evidence is insufficient to claim syndrome-level remission.
- The paper states two low-quality studies (Pu et al., 2021; Ran, 2023) were excluded in an additional meta-analysis; after exclusion, BMI effect attenuated (WMD: −0.302 kg/m²; 95% CI: −0.736 to 0.132; p = 0.173).
- Evident from the text: publication bias was detected for TG by Egger’s test (p = 0.041) and Begg’s test (p = 0.048), though trim-and-fill left the TG result unchanged; 2hOGTT sensitivity analysis was influenced by Panigrahi and Mohanty (2023); one included study was open-label.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 118 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“and the safety of berberine was not evaluated.”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 1 Introduction
What the sources say
- Disputedcites Zamani et al., 2022 sourceExperimental — accuracy not yet measured
The Results section (‘Adverse effects’; page unavailable) evaluates safety by summarizing adverse effects reported in the included studies. It notes that some studies reported no significant adverse effects, while others reported mild to moderate gastrointestinal effects, contrary to the claim that safety was not evaluated. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“A 2022 meta-analysis investigating the effects of berberine on adult cardiovascular risk factors included components of MetS (Zamani et al., 2022)”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 1 Introduction
What the sources say
- Supportedcites Zamani et al., 2022 source
The Results > Study characteristics section lists outcomes including blood pressure, waist circumference, fasting blood glucose, triglycerides, and HDL cholesterol—components of metabolic syndrome. It also reports that some included studies enrolled participants with metabolic syndrome. Page numbers are not available in our copy. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the sensitivity analysis for 2hOGTT indicated that the overall estimate was influenced by the study by Panigrahi A et al. (WMD: −1.884; 95% CI: −2.640 to −1.128) (Panigrahi and Mohanty, 2023)”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.5 Sensitivity analysis
What the sources say
- Supportedcites Panigrahi and Mohanty, 2023 source
The citation identifies the Panigrahi and Mohanty trial as the study considered in the citing authors’ sensitivity analysis. The trial’s Results > Efficacy (Table 3; page not provided) reports 2 h-OGTT outcomes, confirming it is a relevant study. The sensitivity-analysis estimate is the citing authors’ analysis, not a result attributed to the trial. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have confirmed that berberine possesses properties that ameliorate dyslipidemia, insulin resistance, and hypertension (Turner et al., 2008; Xu et al., 2014; Xu et al., 2017; Wang et al., 2018; Rondanelli et al., 2023; Yan et al., 2024).”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 1 Introduction
What the sources say
- Partly supportedcites Turner et al., 2008 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says berberine has insulin-sensitizing properties in rodent models and reports therapeutic potential for dyslipidemia in humans; the Discussion also reports improved symptoms in patients with dyslipidemia. Neither passage supports the hypertension part of the claim, and a search for hypertension and blood pressure found no supporting passage in our copy. (LLM, conf=0.87)
- Not matchedcites Xu et al., 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites Wang et al., 2018 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, there are recent randomized controlled trials (RCTs) on the effects of berberine on MetS components (Wu et al., 2022; Panigrahi and Mohanty, 2023; Ran, 2023).”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 1 Introduction
What the sources say
- Not matchedcites Wu et al., 2022
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Panigrahi and Mohanty, 2023 source
The Methods section (page unavailable) identifies this as a randomized, double-blind, placebo-controlled trial of berberine in people with prediabetes. It assessed glycemic measures, including fasting plasma glucose, which is a metabolic syndrome component. The citation supports the existence of a recent RCT on a component, not a claim that this trial studied every component. (LLM, conf=0.91)
- Not matchedcites Ran, 2023
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
81 more claims
Create a free account to see all 132 claims and every source verdict.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 36
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“we excluded 1 506 studies based on title and abstract not meeting inclusion/exclusion criteria (irrelevant titles and abstracts [n = 97], animal and cell studies [n = 523], improper comparison [n = 611], non-randomized controlled trials [n = 57], comments, letters, and conference abstracts [n = 3], reviews [n = 176])”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.1 Study selection
Reported 1506 · recomputed 1467
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| | Dyslipidemia | 2 | -0.074(-0.726, -0.577) | 41.83 | 0.832 | 0.0 | 0.592 |”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.4 Meta-analysis
Reported -0.074 · recomputed -0.6515
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| | Dyslipidemia | 2 | -0.074(-0.726, -0.577) | 41.83 | 0.832 | 0.0 | 0.592 | | | Other diseases | 6 | -0.693(-1.246, -0.141) | 52.58 | 0.016 | 37.7 | 0.155 |”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.4 Meta-analysis
Reported 100 · recomputed 94.41
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| | 84 | 5 | 0.04(-0.050, 0.043) | 38.50 | 0.878 | 17.4 | 0.298 | | | 90 | 3 | 0.105(0.080, 0.129) | 60.84 | <0.001 | 0.0 | 0.421 | | | ≥112 | 1 | -0.11(-0.205, -0.015) | 13.26 | 0.023 | 0.0 | <0.001 |”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.4 Meta-analysis
Reported 100 · recomputed 112.6
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.4 Meta-analysis
“| | Overall | 9 | -0.016(-0.045, 0.078) | 100 | 0.600 | 83.3 | <0.001 |”
§ Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials > 3 Results > 3.4 Meta-analysis
“(WMD: 0.016 mmol/L; 95% CI: −0.045 to 0.078; p = 0.60)”
3 more findings
Create a free account to see every finding of this check.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity is assessed using the I 2 statistic, with I 2 > 50% indicating bigger heterogeneity (Higgins et al., 2003).”
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“The quality of the included studies was assessed using the Cochrane Collaboration ’ s Risk of Bias Tool version 2 (RoB 2) for randomized controlled trials (Sterne et al., 2019).”
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854 · cited 1×
“It is estimated that one-quarter of the global population is affected by MetS, with projections suggesting this fi gure could rise to approximately 53% by 2035 (Saklayen, 2018; Belhayara et al., 2020; Collaborators, 2020).”
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
The Global Epidemic of the Metabolic Syndrome
Saklayen, M. G. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0812-z · Cited by 3,990 · cited 1×
“It is estimated that one-quarter of the global population is affected by MetS, with projections suggesting this fi gure could rise to approximately 53% by 2035 (Saklayen, 2018; Belhayara et al., 2020; Collaborators, 2020).”
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.07.010 · Cited by 1,313
Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.010 · Cited by 730
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573
Self-citationTurner, N., Li, J.-Y., Gosby, A., To, S. W. C., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., et al. (2008) · Diabetes · doi:10.2337/db07-1552 · Cited by 535
Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458
Gu, Y., Zhang, Y., Shi, X., Li, X., Hong, J., Chen, J., Gu, W., Lu, X., Xu, G., & Ning, G. (2010) · Talanta · doi:10.1016/j.talanta.2010.01.015 · Cited by 190
Self-citationXu, Z., Feng, W., Shen, Q., Yu, N., Yu, K., Wang, S., Chen, Z., Shioda, S., & Guo, Y. (2017) · Aging and disease · doi:10.14336/ad.2016.0620 · Cited by 142
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Pérez-Rubio, K. G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Espinel-Bermúdez, M. C. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0183 · Cited by 113
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12294 · Cited by 105 · cited 10×
“Of the 12 eligible trials, 9 assessed TG (Kong et al., 2004; Zhang et al., 2008; Perez-Rubio et al., 2013; An et al., 2014; Pu et al., 2021; Zhao et al., 2021a; Wu et al., 2022; Ran, 2023; Wang et al., 2016b), 9 assessed HDL-C (Kong et al., 2004; Zhang et al., 2008; Perez-Rubio et al., 2013; An et…”
InfluentialSelf-citationBerberine Promotes Glucose Consumption Independently of AMP-Activated Protein Kinase Activation
Xu, M., Xiao, Y., Yin, J., Hou, W., Yu, X., Shen, L., Liu, F., Wei, L., & Jia, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103702 · Cited by 94 · cited 2×
“It exerts its effects through the activation of AMP-activated protein kinase, enhancing glucose uptake in peripheral tissues, promoting lipid metabolism, and in fl uencing fasting plasma glucose (FPG) and TG levels (Turner et al., 2008; Xu et al., 2014; Wang et al., 2018).”
Wu, C., Zhao, Y. L., Zhang, Y., Yang, Y., Su, W., Yang, Y., Sun, L., Zhang, F., Yu, J., Wang, Y., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.011 · Cited by 94
Self-citationWu, S., Liu, Z., & Ho, S. C. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9496-7 · Cited by 91
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015045 · Cited by 91 · cited 1×
“Furthermore, a 2023 meta-analysis (Xie et al., 2022) reported that berberine intervention signi fi cantly reduced FPG and 2hOGTT levels; however, this meta-analysis only included T2DM patients, while our meta-analysis evaluated berberine ’ s effect in a broader population.”
Self-citationShidfar, F., Ebrahimi, S., Hosseini, S., Heydari, I., Shidfar, S., & Hajhassani, G. (2012) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2012.1155 · Cited by 78
Metabolic syndrome and lifestyle modification
Takahara, M., & Shimomura, I. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9294-8 · Cited by 70
(2012) · Europe PMC (PubMed Central) · Cited by 62
Wang, L., Ye, X., Hua, Y., & Song, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.110 · Cited by 59
Zhao, J. V., Yeung, W.-F., Chan, Y.-H., Vackova, D., Leung, J. Y. Y., Ip, D. K. M., Zhao, J., Ho, W.-K., Tse, H.-F., & Schooling, C. M. (2021) · Nutrients · doi:10.3390/nu13082550 · Cited by 58 · cited 8×
“Of the 12 eligible trials, 9 assessed TG (Kong et al., 2004; Zhang et al., 2008; Perez-Rubio et al., 2013; An et al., 2014; Pu et al., 2021; Zhao et al., 2021a; Wu et al., 2022; Ran, 2023; Wang et al., 2016b), 9 assessed HDL-C (Kong et al., 2004; Zhang et al., 2008; Perez-Rubio et al., 2013; An et…”
InfluentialLiu, J., Hu, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.020 · Cited by 54 · cited 1×
“These trials involved populations with dyslipidemia (Kong et al., 2004; Wang et al., 2016a; Zhao et al., 2021b; Wu et al., 2022), T2DM-associated dyslipidemia (Zhang et al., 2008), hyperglycemia (Ming et al., 2021), drug-induced impaired fasting glucose (IFG) (Pu et al., 2021), prediabetes…”
Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00942-7 · Cited by 52
Iloon Kashkooli, R., Najafi, S. S., Sharif, F., Hamedi, A., Hoseini Asl, M. K., Najafi Kalyani, M., & Birjandi, M. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.25067 · Cited by 51
Haro, J. M., Novick, D., Belger, M., & Jones, P. B. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.001 · Cited by 49
Current diagnostic criteria identify risk for type 2 diabetes too late
Bergman, M., Buysschaert, M., Ceriello, A., Hussain, A., Mohan, V., Sesti, G., & Tuomilehto, J. O. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00039-6 · Cited by 37
Yang, L., Zhu, W., Zhang, X., Zhou, X., Wu, W., & Shen, T. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154716 · Cited by 34
Sharebiani, H., Mokaram, M., Mirghani, M., Fazeli, B., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16111641 · Cited by 34
Blais, J. E., Huang, X., & Zhao, J. V. (2022) · medRxiv · doi:10.1101/2022.06.20.22276676 · Cited by 31
Cao, R. Y., Zheng, Y., Zhang, Y., Jiang, L., Li, Q., Sun, W., Gu, W., Cao, W., Zhou, L., Zheng, H., et al. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500762 · Cited by 31
Self-citationPanigrahi, A., & Mohanty, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01442-y · Cited by 30
(2017) · PubMed · Cited by 29
Pu, Z., Sun, Y., Jiang, H., Hou, Q., Yan, H., Wen, H., & Li, G. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500920 · Cited by 29
Zamani, M., Zarei, M., Nikbaf-Shandiz, M., Hosseini, S., Shiraseb, F., & Asbaghi, O. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1013055 · Cited by 28
Zhang, M., Liu, J., Yu, C., Tang, S., Jiang, G., Zhang, J., Zhang, H., Xu, J., & Xu, W. (2022) · Antioxidants · doi:10.3390/antiox11122370 · Cited by 28
[Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia].
Wang, L., Peng, L.-Y., Wei, G., & Hui, G. (2016) · PubMed · Cited by 26
Zilaee, M., Kermany, T., Tavalaee, S., Salehi, M., Ghayour-Mobarhan, M., & Ferns, G. A. A. (2014) · Phytotherapy Research · doi:10.1002/ptr.5117 · Cited by 24
Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234300 · Cited by 21
Aryaeian, N., Sedehi, S. K., Khorshidi, M., Zarezadeh, M., Hosseini, A. F., & Shahram, F. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102331 · Cited by 21
Pennybaker, S. J., Roach, B. J., Fryer, S. L., Badathala, A., Wallace, A., Mathalon, D. H., & Marton, T. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05939-z · Cited by 21
Sangouni, A. A., Alizadeh, M., Jamalzehi, A., Hosseinzadeh, M., & Parastouei, K. (2023) · Phytotherapy Research · doi:10.1002/ptr.7741 · Cited by 19
Increased Oxidative Stress in Cultured 3T3-L1 Cells was Attenuated by Berberine Treatment
Dong, S., Yasui, N., Negishi, H., Kishimoto, A., Sun, J., & Ikeda, K. (2015) · Natural Product Communications · doi:10.1177/1934578x1501000626 · Cited by 19
Asemani, S., Montazeri, V., Baradaran, B., Tabatabaiefar, M. A., & Pirouzpanah, S. (2018) · PubMed Central · Cited by 13
Belhayara, M. I., Mellouk, Z., Hamdaoui, M. S., Bachaoui, M., Khéroua, O., & Malaisse, W. J. (2020) · Nutrients · doi:10.3390/nu12030727 · Cited by 13
Zhao, J. V., Huang, X., Zhang, J., Chan, Y., Tse, H., & Blais, J. E. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.08.016 · Cited by 13
Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
Zhao, M., Lü, J., Li, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26635-8 · Cited by 12
Rondanelli, M., Gasparri, C., Petrangolini, G., et al. (2023) · PubMed · doi:10.26355/eurrev_202307_33142 · Cited by 12
Ruíz-Herrera, V. V., Navarro-Lara, S. A., Andrade-Villanueva, J. F., Álvarez-Zavala, M., Sánchez-Reyes, K., Toscano-Piña, M., Méndez-Clemente, A. S., Martínez-Ayala, P., Valle-Rodríguez, A., & González-Hernández, L. A. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231196600 · Cited by 11
Asemani, S., Montazeri, V., Baradaran, B., Tabatabiefar, M., & Pirouzpanah, S. (2018) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2018.2212 · Cited by 11
Rostami, H., Babaali, F., Moradi, L., Golfakhrabadi, F., & Abdi, L. (2023) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v18i3.13015 · Cited by 9
Yan, J., He, L., Zhiwu, H., et al. (2024) · Foods · doi:10.3390/foods13101428 · Cited by 9
Cesarone, M. R., Hu, S., Belcaro, G., Cornelli, U., Feragalli, B., Corsi, M., SCIPIONE, V., SCIPIONE, C., Cotellese, R., Hosoi, M., et al. (2023) · Minerva Gastroenterology · doi:10.23736/s2724-5985.23.03540-4 · Cited by 5
Research works printed but not linked: 1
- Ran, 2023, Clinical study of berberine in the treatment of low HDL-C.
Cited by
Korsapati, A. R., Korsapati, H. R., & Peddireddy, V. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105355 · Cited by 8
Šantić, R., Martinovic, L., Pavlović, N., Martinović, D., Vrdoljak, J., Kumrić, M., Vilović, M., & Božić, J. (2026) · Molecules · doi:10.3390/molecules31111840 · Cited by 9
“…by P-glycoprotein efflux and first-pass metabolism, is partially resolved by microbial conversion to more bioavailable forms, though CYP3A4 inhibition introduces drug interaction risk and gastrointestinal adverse effects above 1.5 g/day remain the primary barrier to standardisation [173,185,187].”
InfluentialTawanwongsri, W., Mordmuang, A., Phenwan, T., & Siri-Archawawat, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1680647 · Cited by 4
Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions
Marie, O., & Abu-Elsaoud, A. M. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71575 · Cited by 8
“Mechanistic investigations have revealed that nat-ural compounds modulate multiple pathways involved in energy homeostasis, adipose tissue biology, inflammation, and oxidative stress (Liu, Liu, et al. 2025).”
InfluentialMansour, M. F., Behairy, A., Khamis, T., Mohammed, H. A., Alsemeh, A. E., Eltaweel, A. M., & El-Emam, M. M. A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2026.159716 · Cited by 3
Metadata
- Authors
- Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H.
- Affiliations
- Chengdu University of Traditional Chinese Medicine (CN)
- Nanjing University of Chinese Medicine (CN)
- Institute of Basic Theory for Chinese Medicine (CN)
- Guangzhou University of Chinese Medicine (CN)
- Corresponding author
- Hu, Jingqing
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2025-07-16
- Volume
- 16
- Pages
- 1572197-1572197
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC12307485
- OpenAlex
- W4412465953
- Cited by
- 24
- References
- 59
- Citations by year
- 2026: 21 · 2025: 3
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- China Academy of Traditional Chinese Medicine
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- berberine, metabolic syndrome, triglycerides, fasting blood glucose, waist circumference, LDL cholesterol, total cholesterol, blood pressure, body mass index, oral glucose tolerance, insulin resistance, type 2 diabetes prevention, drug safety, adverse events, hepatotoxicity, gastrointestinal adverse effects, drug interactions, herbal medicine, antidiabetic drugs, lipid metabolism, antihypertensive drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.